Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene to Present Data of Its PD-L1/4-1BB Bispecific Antibody ATG-101 and ERK1/2 Inhibitor ATG-017 at SITC 2021

SHANGHAI and HONG KONG, Oct. 15, 2021 /PRNewswire/ -- The 36th Annual Meeting of the Society for Im...

2021-10-15 13:33 3211

Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

SHANGHAI and HONG KONG, Aug. 24, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-08-24 08:30 3216

Antengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets

SHANGHAI and HONG KONG, Aug. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-08-09 08:30 3762

Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 2, 2021 /PRNewswire/ -- Antengene Corporation L...

2021-08-02 07:29 6149

Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections

SHANGHAI and HONG KONG, July 26, 2021 /PRNewswire/ -- In June 2021, results from a preclinical stud...

2021-07-26 08:44 3380

Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections

Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

SHANGHAI and HONG KONG, July 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-07-22 09:27 3053

Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies

SHANGHAI and HONG KONG, July 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-07-14 10:00 22114

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

SHANGHAI and HONG KONG, July 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-07-06 08:00 4508

Antengene Provides an Update on Its Latest Developments

* Announces two new in-house discovered assets - ATG-031, a potential first-in-class anti-CD24 mo...

2021-06-18 14:10 12576

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease...

2021-06-09 08:00 3534

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

SHANGHAI and HONG KONG, June 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-06-04 08:00 3704

Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021

SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-06-02 08:00 4563

Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021

SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-06-02 08:00 3202

Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome

SHANGHAI and HONG KONG, May 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-05-28 08:00 3668

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

SHANGHAI and HARTFORD, Conn., May 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengen...

2021-05-25 08:00 4509

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limite...

2021-05-17 20:35 4233

Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial

SHANGHAI and HONG KONG, May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2021-05-17 08:00 3322

Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China

SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-05-14 08:40 4687

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Today, Antengene Corporation Limited ("Antenge...

2021-05-14 08:00 4976

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer

SHANGHAI and HONG KONG, May 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-05-13 08:00 3523